Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
19 déc. 2023 16h05 HE
|
Compass Pathways
LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways appoints Teri Loxam as Chief Financial Officer
07 déc. 2023 07h00 HE
|
Compass Pathways
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
06 déc. 2023 16h00 HE
|
Compass Pathways
LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways to participate in upcoming Evercore investor conference
24 nov. 2023 08h00 HE
|
Compass Pathways
LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
15 nov. 2023 04h00 HE
|
Compass Pathways
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened...
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
02 nov. 2023 07h00 HE
|
COMPASS Pathways
Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sitesSecured up to $285 million private placement financing with $125 million upfrontCash position at September 30,...
COMPASS Pathways announces CFO transition
26 oct. 2023 08h00 HE
|
COMPASS Pathways
LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based...
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023
24 oct. 2023 16h01 HE
|
COMPASS Pathways
LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
18 sept. 2023 16h31 HE
|
COMPASS Pathways
LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
06 sept. 2023 04h00 HE
|
COMPASS Pathways
LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...